| Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial T Yau, YK Kang, TY Kim, AB El-Khoueiry, A Santoro, B Sangro, I Melero, ... JAMA oncology 6 (11), e204564-e204564, 2020 | 960 | 2020 |
| Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study MS Lee, BY Ryoo, CH Hsu, K Numata, S Stein, W Verret, SP Hack, ... The Lancet Oncology 21 (6), 808-820, 2020 | 445 | 2020 |
| The role of angiogenesis in hepatocellular carcinoma MA Morse, W Sun, R Kim, AR He, PB Abada, M Mynderse, RS Finn Clinical Cancer Research 25 (3), 912-920, 2019 | 444 | 2019 |
| Liver stem cells and hepatocellular carcinoma L Mishra, T Banker, J Murray, S Byers, A Thenappan, AR He, K Shetty, ... Hepatology 49 (1), 318-329, 2009 | 403 | 2009 |
| Progenitor/stem cells give rise to liver cancer due to aberrant TGF-β and IL-6 signaling Y Tang, K Kitisin, W Jogunoori, C Li, CX Deng, SC Mueller, HW Ressom, ... Proceedings of the National Academy of Sciences 105 (7), 2445-2450, 2008 | 391 | 2008 |
| Intratumoral CD3 and CD8 T-cell densities associated with relapse-free survival in HCC A Gabrielson, Y Wu, H Wang, J Jiang, B Kallakury, Z Gatalica, S Reddy, ... Cancer immunology research 4 (5), 419-430, 2016 | 279 | 2016 |
| The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-β signaling L Lin, R Amin, GI Gallicano, E Glasgow, W Jogunoori, JM Jessup, ... Oncogene 28 (7), 961-972, 2009 | 259 | 2009 |
| Nivolumab (NIVO)+ ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. T Yau, YK Kang, TY Kim, AB El-Khoueiry, A Santoro, B Sangro, I Melero, ... Journal of Clinical Oncology 37 (15_suppl), 4012-4012, 2019 | 248 | 2019 |
| Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma AX Zhu, AR Abbas, MR de Galarreta, Y Guan, S Lu, H Koeppen, W Zhang, ... Nature medicine 28 (8), 1599-1611, 2022 | 243 | 2022 |
| Phase I study of single-agent utomilumab (PF-05082566), a 4-1BB/CD137 agonist, in patients with advanced cancer NH Segal, AR He, T Doi, R Levy, S Bhatia, MJ Pishvaian, R Cesari, ... Clinical Cancer Research 24 (8), 1816-1823, 2018 | 238 | 2018 |
| A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract … DY Oh, AR He, S Qin, LT Chen, T Okusaka, A Vogel, JW Kim, ... Journal of Clinical Oncology 40 (4_suppl), 378-378, 2022 | 198 | 2022 |
| Hepatic stem cells and transforming growth factor β in hepatocellular carcinoma A Majumdar, SA Curley, X Wu, P Brown, JP Hwang, K Shetty, ZX Yao, ... Nature reviews Gastroenterology & hepatology 9 (9), 530-538, 2012 | 161 | 2012 |
| Recent developments and therapeutic strategies against hepatocellular carcinoma M Yarchoan, P Agarwal, A Villanueva, S Rao, LA Dawson, T Karasic, ... Cancer research 79 (17), 4326-4330, 2019 | 135 | 2019 |
| Nivolumab (NIVO)+ ipilimumab (IPI)+ cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. T Yau, V Zagonel, A Santoro, M Acosta-Rivera, SP Choo, A Matilla, AR He, ... Journal of Clinical Oncology 38 (4_suppl), 478-478, 2020 | 121 | 2020 |
| Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection NJ Shah, G Al-Shbool, M Blackburn, M Cook, A Belouali, SV Liu, ... Journal for immunotherapy of cancer 7, 1-8, 2019 | 114 | 2019 |
| Phase 2, multicenter, open‐label study of tigatuzumab (CS‐1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy … A Forero‐Torres, JR Infante, D Waterhouse, L Wong, S Vickers, ... Cancer medicine 2 (6), 925-932, 2013 | 107 | 2013 |
| Systemic treatment for advanced hepatocellular carcinoma M Bouattour, N Mehta, AR He, EI Cohen, JC Nault Liver cancer 8 (5), 341-358, 2019 | 99 | 2019 |
| βII‐Spectrin (SPTBN1) suppresses progression of hepatocellular carcinoma and Wnt signaling by regulation of Wnt inhibitor kallistatin X Zhi, L Lin, S Yang, K Bhuvaneshwar, H Wang, Y Gusev, MH Lee, ... Hepatology 61 (2), 598-612, 2015 | 99 | 2015 |
| A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies JF Deeken, R Slack, GJ Weiss, RK Ramanathan, MJ Pishvaian, J Hwang, ... Cancer chemotherapy and pharmacology 71, 627-633, 2013 | 83 | 2013 |
| A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies JF Deeken, H Wang, M Hartley, AK Cheema, B Smaglo, JJ Hwang, AR He, ... Cancer chemotherapy and pharmacology 81, 587-596, 2018 | 82 | 2018 |
